ea0032p841 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013
Pivonello Rosario
, Petersenn Stephan
, Gu Feng
, Trovato Andrew
, Hughes Gareth
, Ligueros-Saylan Monica
, Roberto Salgado Luiz
, Lacroix Andre
, Schopohl Jochen
, Biller Beverly
Introduction: Pasireotide normalized or reduced UFC in patients with Cushings disease in a large, 12-month study. This analysis evaluates the effects of pasireotide on the signs/symptoms of Cushings disease according to the degree of UFC control.Methods: Adult patients (n=162) with persistent/recurrent or de novo Cushings disease were randomized to pasireotide 600/900 μg s.c. bid. Dose titration (max: 1200 μg...